Measles, Mumps, Rubella vaccination ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 107 | Juvenile idiopathic arthritis | 1 |
107. Juvenile idiopathic arthritis
Clinical trials : 441 / Drugs : 282 - (DrugBank : 56) / Drug target genes : 52 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00731965 (ClinicalTrials.gov) | May 2008 | 6/8/2008 | Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis | Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine | Arthritis, Juvenile Rheumatoid | Biological: Measles, Mumps, Rubella vaccination | N.M. Wulffraat | University Medical Centre Groningen;VU University Medical Center;Maastricht University Medical Center;Erasmus Medical Center | Completed | 4 Years | 9 Years | Both | 140 | Phase 4 | Netherlands |